血红素加氧酶-1在慢性肝病发病中的作用研究进展*

doi:10.3969/j.issn.1672-5069.2015.02.031

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (3): 321-324.doi: 10.3969/j.issn.1672-5069.2015.02.031

血红素加氧酶-1在慢性肝病发病中的作用研究进展^*

嵇小琴综述, 李磊审校

230001 合肥市安徽省军区第四干休所（嵇小琴）; 安徽医科大学附属省立医院感染病科（李磊）

收稿日期:2014-12-02 出版日期:2015-05-10 发布日期:2016-02-19
通讯作者: 李磊,E-mail：lilei0403@163.com E-mail:771910291@qq.com
作者简介:嵇小琴, 女,38岁,主治医师。主要从事老年肝病的诊治研究。E-mail: 771910291@qq.com
基金资助:
安徽省科技厅自然科学基金（编号：1208085QH147）; 安徽省教育厅自然基金（编号：KJ2012A174）

Heme oxygenase-1 in the pathogenesis of chronic liver diseases

Ji Xiaoqin, Li Lei

Department of Infectious Diseases, Anhui Provincial Hospital Affiliated to Anhui Medical University,Hefei 230001,China[Abstract] Heme oxygenase-1（HO-1） is a microsomal enzyme and rate-limiting enzyme that catalyzes the degradation of heme into biliverdin, iron atoms and carbon monoxide （CO）. It is reported that HO-1 and its breakdown products play vital physiological roles in anti-inflammation, anti-oxidation and regulation of apoptosis. Its roles in the pathogenesis of liver diseases in recent years have gradually be elucidated,and it is promising for an option in the treatment of chronic liver disease in the future. In this paper,we will review the research progress about HO-1 in the viral hepatitis,liver fibrosis,hepatocellular carcinoma and hepatic ischemia-reperfusion injury.

Received:2014-12-02 Online:2015-05-10 Published:2016-02-19

摘要/Abstract

摘要： 血红素加氧酶-1（HO-1）作为一种微粒体酶,是催化血红素的降解成胆绿素、铁原子和一氧化碳(CO) 反应的限速酶。既往研究表明HO-1及其代谢产物在抗炎、抗氧化、调节细胞凋亡等方面发挥着重要的生理作用。近年来,HO-1在肝脏疾病发病中的作用逐渐显现,且被认为在慢性肝病的治疗方面具有良好的应用前景。本文重点介绍HO-1在病毒性肝炎、肝纤维化、肝细胞癌以及肝脏缺血再灌注损伤发病中的作用研究进展。

关键词: 病毒性肝炎, 肝细胞癌, 缺血再灌注损伤, 血红素加氧酶-1

Key words: Viral hepatitis, Hepatocellular carcinoma, Ischemia-reperfusion injury, Heme oxygenase-1

嵇小琴, 李磊. 血红素加氧酶-1在慢性肝病发病中的作用研究进展^*[J]. 实用肝脏病杂志, 2015, 18(3): 321-324.

Ji Xiaoqin, Li Lei. Heme oxygenase-1 in the pathogenesis of chronic liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 321-324.

参考文献

[1] Gozzelino R,Jeney V,Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol,2010,50:323-354.
[2] Paine A,Eiz-Vesper B,Blasczyk R,et al. Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem Pharmacol,2010,80（12）:1895-1903.
[3] Vijayan V,Mueller S,Baumgart-Vogt E,et al. Heme oxygenase-1 as a therapeutic target in inflammatory disorders of the gastrointestinal tract. World J Gastroenterol,2010,16（25）:3112-3119.
[4] Farombi EO,Surh YJ. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J Biochem Mol Biol,2006,39（5）:479-491.
[5] Suliburk JW,Ward JL,Helmer KS,et al. Ketamine-induced hepatoprotection:the role of heme oxygenase-1. Am J Physiol Gastrointest Liver Physiol,2009,296（6）:G1360-1369.
[6] Gozzelino R,Jeney V,Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol,2010,50:323-354.
[7] Soares MP,Marguti I,Cunha A,et al. Immunoregulatory effects of HO-1:how does it work Curr Opin Pharmacol,2009,9（4）:482-489.
[8] Biburger M,Theiner G,Schadle M,et al. Pivotal advance: Heme oxygenase 1 expression by human CD4 + T cells is not sufficient for their development of immunoregulatory capacity. J Leukoc Biol,2010,87（2）:193-202.
[9] Farombi EO,Surh YJ. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J Biochem Mol Biol,2006,39（5）:479-491.
[10] Abdalla MY,Britigan BE,Wen F,et al Down-regulation of heme oxygenase-1 by hepatitis C virus infection in vivo and by the in vitro expression of hepatitis C core protein. J Infect Dis,2004,190（6）:1109-1118.
[11] Protzer U,Seyfried S,Quasdorff M,et al. Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. Gastroenterology,2007,133（4）:1156-1165.
[12] 李磊,韩华,金坤,等. 血红素加氧酶-1表达对HBV复制的反向调控作用. 肝脏,2013,18（10）:592-596.
[13] Lin L,Hu J. Inhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compounds. J Virol,2008,82（5）:2305-2312.
[14] Zhu Z,Wilson AT,Mathahs MM,et al. Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology,2008,48（5）:1430-1439.
[15] Fillebeen C,Rivas-Estilla AM, Bisaillon M,et al. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem,2005,280（10）:9049-9057.
[16] Yuasa K,Naganuma A,Sato K,et al. Zinc is a negative regulator of hepatitis C virus RNA replication. Liver Int,2006,26（9）:1111-1118.
[17] Zhu Z,Wilson AT,Luxon BA,et al. Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity:mechanism for the antiviral effects of heme oxygenase Hepatology,2010,52（6）:1897-1905.
[18] Hou W,Tian Q,Zheng J,et al. Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. Gastroenterology,2010,138（5）:1909-1919.
[19] Lehmann E,El-Tantawy WH,Ocker M,et al. The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology,2010,51（2）:398-404.
[20] Kalliolias GD,Ivashkiv LB. Overview of the biology of type I interferons. Arthritis Res Ther,2010,12 （Suppl 1）:S1.
[21] Lehmann E,El-Tantawy WH,Ocker M,et al. The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology,2010,51（2）:398-404.
[22] Lundvig DM,Immenschuh S,Wagener FA. Heme oxygenase, inflammation,and fibrosis: the good,the bad,and the ugly Front Pharmacol,2012,3:81.
[23] Bessa SS,Mohamed Ali EM,Abd El-Wahab Ael-S,et al. Heme oxygenase-1 mRNA expression in egyptian patients with chronic liver disease. Hepat Mon,2012,12（4）:278-285.
[24] Guo SB, Li Q, Duan ZJ, et al. Octreotide attenuates liver fibrosis by inhibiting hepatic heme oxygenase-1 expression. Mol Med Rep,2015,11（1）:83-90.
[25] Wang QM,Du JL,Duan ZJ,et al. Inhibiting heme oxygenase-1 attenuates rat liver fibrosis by removing iron accumulation. World J Gastroenterol,2013,19（19）:2921-2934.
[26] Wang F,Duan ZJ,Sun YJ. Influence of heme oxygenase-1 expression on immune liver fibrosis induced by cobalt protoporphyrin in rats. World J Gastroenterol,2009,15（24）:3009-3014.
[27] Yang H,Zhao LF,Zhao ZF,et al. Heme oxygenase-1 prevents liver fibrosis in rats by regulating the expression of PPARγ and NF-κB. World J Gastroenterol,2012,18（14）:1680-1688.
[28] Barikbin R,Neureiter D,Wirth J,et al. Induction of heme oxygenase 1 prevents progression of liver fibrosis in Mdr2 knockout mice. Hepatology,2012,55（2）:553-562.
[29] Zou C,Zhang H,Li Q,et al. Heme oxygenase-1:a molecular brake on hepatocellular carcinoma cell migration. Carcinogenesis, 2011,32（12）:1840-1848.
[30] Sass G,Leukel P,Schmitz V,et al. Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. Int J Cancer,2008,123（6）:1269-1277.
[31] Sun L,Shi T,Qiao H,et al. Hepatic overexpression of heme oxygenase-1 improves liver allograft survival by expanding T regulatory cells. J Surg Res,2011,166（2）:e187-194.
[32] Ben-Ari Z1,Issan Y,Katz Y,et al. Induction of heme oxygenase-1 protects mouse liver from apoptotic ischemia/reperfusion injury. Apoptosis,2013,18（5）:547-555.
[33] Wang CF,Wang ZY,Tao SF,et al. Preconditioning donor liver with Nodosin perfusion lessens rat ischemia reperfusion injury via heme oxygenase-1 upregulation. J Gastroenterol Hepatol,2012,27（4）:832-840.
[34] Matsumi J,Morimatsu H,Matsusaki T,et al. Heme breakdown and ischemia/reperfusion injury in grafted liver during living donor liver transplantation. Int J Mol Med,2012,29（2）:135-140.
[35] Tamura T,Kondo T,Ogawa K,et al. Protective effect of heme oxygenase-1 on hepatic ischemia-reperfusion injury through inhibition of platelet adhesion to the sinusoids. J Gastroenterol Hepatol,2013,28（4）:700-706.
[36] Kim SJ,Eum HA,Billiar TR,et al. Role of heme oxygenase 1 in TNF/TNF receptor-mediated apoptosis after hepatic ischemia/reperfusion in rats. Shock,2013,39（4）:380-388.
[37] Yun N,Cho HI,Lee SM. Impaired autophagy contributes to hepatocellular damage during ischemia/reperfusion:heme oxygenase-1 as a possible regulator. Free Radic Biol Med,2014,68:168-177.
[38] Wang Y,Shen J,Xiong X,et al. Remote ischemic preconditioning protects against liver ischemia-reperfusion injury via heme oxygenase-1-induced autophagy. PLoS One,2014,9（6）:e98834.

血红素加氧酶-1在慢性肝病发病中的作用研究进展^*

Heme oxygenase-1 in the pathogenesis of chronic liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[2]	林秋香, 王雪雯, 黄祖雄, 潘晨. 灯盏花素对肝脏缺血再灌注损伤大鼠肝脏和肠黏膜屏障功能的保护作用*[J]. 实用肝脏病杂志, 2019, 22(5): 636-639.
[3]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[4]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[5]	刘杏, 赵树立, 张殿隆. 七氟烷吸入时机对肝脏部分切除术患者肝脏缺血再灌注损伤的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 728-731.
[6]	王艳, 苏峰, 李园园, 李舒. 蜂毒溶血肽改善非酒精性脂肪肝大鼠肝组织脂肪沉积作用及其机制研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 474-477.
[7]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[8]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[9]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[10]	乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424.
[11]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[12]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[13]	幸奠奎,程婧. ¹⁸F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 252-254.
[14]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[15]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.